Leniolisib Phosphate Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 70 mg

Reference Brands: Joenja (USA/EU)

Category: Immune Disorder

Product Description:

Leniolisib phosphate, marketed under the brand name Joenja, is a targeted kinase inhibitor used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS). It is indicated for patients aged twelve years and older who are diagnosed with this rare primary immunodeficiency disorder. APDS is caused by mutations in the PIK3CD or PIK3R1 genes, which play a critical role in regulating the development and function of immune cells.

These genetic abnormalities lead to impaired maturation of B cells and T cells, resulting in weakened immune responses and an increased susceptibility to recurrent bacterial and viral infections. Leniolisib phosphate works by selectively inhibiting the PI3Kδ enzyme, helping to restore balance in immune signaling pathways and improve immune cell function. Unlike broad immunosuppressive therapies, this targeted approach addresses the underlying molecular mechanism of the disease.

Leniolisib phosphate is administered orally and is intended for long-term management under specialist supervision. As a precision therapy developed for a genetically defined condition, its use requires appropriate diagnostic confirmation and ongoing clinical monitoring to ensure safety and therapeutic effectiveness.